news Idarucizumab Promising in Dabigatran-Treated Patients With ICH REVERSE-AD is an ongoing phase 3 cohort study evaluating the reversal effects of idarucizumab on dabigatran. By Kathleen Moore, RN Publish Date February 19, 2016
